Micardis® / MicardisPlus® Program for Therapy Optimization With Telmisartan in Cardiovascular Diseases (PROTEKT)

Boehringer Ingelheim

Status: Completed

Conditions: Hypertension

Treatments: Drug: MicardisPlus®; Drug: Micardis®

Study type: Observational

Funder types: Industry

Identifiers

NCT02262637

502.441

502.442, 502.443 (Other Identifier)

Details and patient eligibility

About

Study to evaluate efficacy and tolerability of Micardis®/MicardisPlus® under usual daily-practice prescribing-conditions with emphasis on effects on endorgan damage in the clientele of cardiologists, nephrologists, and diabetologists

Enrollment: 4,814 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age >= 18 years

Exclusion criteria

• Age < 18 years

Trial design

4,814 participants in 3 patient groups

Hypertensive patients - Cardiologists

Treatment:

Drug: MicardisPlus®

Drug: Micardis®

Hypertensive patients - Nephrologists

Treatment:

Drug: MicardisPlus®

Drug: Micardis®

Hypertensive patients - Diabetologists

Treatment:

Drug: MicardisPlus®

Drug: Micardis®